Invasive fungal infections are increasingly recognized in immunocompromised hosts. Current diagnostic techniques are limited by low sensitivity and prolonged turnaround times. We review emerging diagnostic technologies and platforms for diagnosing the clinically invasive disease caused by , , and Mucorales.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916227 | PMC |
| http://dx.doi.org/10.3390/jof7020127 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Asian Perspective on Hepatitis B Virus and Hepatitis C Virus Elimination.
Viruses
December 2024
NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain significant public health challenges in Asia, affecting millions and contributing to substantial morbidity and mortality. The prevalence of these infections varies across the region, with factors such as vaccination coverage, healthcare infrastructure, and sociocultural barriers influencing the epidemiology of both viruses. The persistent burden of chronic HBV, particularly in older populations, and the evolving HCV genotype landscape highlight the need for targeted, region-specific strategies.
View Article and Find Full Text PDFLeveraging Next-Generation Sequencing Application from Identity to Purity Profiling of Nucleic Acid-Based Products.
Pharmaceutics
December 2024
Gennova Biopharmaceuticals Ltd., ITBT Park, Hinjawadi Phase 2 Rd, Hinjewadi Rajiv Gandhi Infotech Park, Hinjawadi, Pune 411057, India.
: The nucleic acid-based product (NAP) portfolio is expanding continuously and provides safer curative options for many disease indications. Nucleic acid-based products offer several advantages compared to proteins and virus-based products. They represent an emerging field; thus, their quality control and regulatory landscape is evolving to ensure adequate quality and safety.
View Article and Find Full Text PDFDecoding the Biobased Blueprint: Key Players and Evolutionary Trends in Materials Innovation.
Polymers (Basel)
January 2025
Department of Mechanical Engineering, Debre Markos University, Debre Markos 251, Ethiopia.
In the rapidly evolving biobased materials innovation landscape, our research identifies key players and explores the evolutionary perspective of biobased innovation, offering insights into promising research areas to be further developed by biobased material scientists in search of exploiting their knowledge in novel applications. Despite the crucial role of these materials in promoting sustainable production and consumption models, systematic studies on the current innovation terrain are lacking, leaving gaps in understanding key players, emerging technologies, and market trends. To address this void, we focused on examining patents related to biobased monomers and polymers, aiming to describe the innovation strategies and business dynamics of leading assignees.
View Article and Find Full Text PDFA Comprehensive Review of the Diagnostics for Pediatric Tuberculosis Based on Assay Time, Ease of Operation, and Performance.
Microorganisms
January 2025
Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.
Pediatric tuberculosis (TB) is still challenged by several diagnostic bottlenecks, imposing a high TB burden in low- and middle-income countries (LMICs). Diagnostic turnaround time (TAT) and ease of operation to suit resource-limited settings are critical aspects that determine early treatment and influence morbidity and mortality. Based on TAT and ease of operation, this article reviews the evolving landscape of TB diagnostics, from traditional methods like microscopy and culture to cutting-edge molecular techniques and biomarker-based approaches.
View Article and Find Full Text PDFNuclear Medicine and Molecular Imaging in Urothelial Cancer: Current Status and Future Directions.
Cancers (Basel)
January 2025
Urology Department, South Metropolitan Health Service, Murdoch, WA, 6150, Australia.
: The role of molecular imaging in urothelial cancer is less defined than other cancers, and its utility remains controversial due to limitations such as high urinary tracer excretion, complicating primary tumour assessment in the bladder and upper urinary tract. This review explores the current landscape of PET imaging in the clinical management of urothelial cancer, with a special emphasis on potential future advancements including emerging novel non-F FDG PET agents, PET radiopharmaceuticals, and PET-MRI applications. : We conducted a comprehensive literature search in the PubMed database, using keywords such as "PET", "PET-CT", "PET-MRI", "FDG PET", "Urothelial Cancer", and "Theranostics".
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!